News

Madrigal Pharma Bolstered By Equity Infusion, Buy Into 2024 (NASDAQ:MDGL)

8 Mins read

Madrigal Pharmaceuticals (NASDAQ:MDGL) is currently transitioning from the clinical trial stage to preparing market-ready solutions primarily aimed at addressing non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their leading candidate, Resmetirom, is now in Phase III clinical trials and is anticipated to enter the market

Read the full article here

Related posts
News

Supercharge SCHD ETF With Big Dividend Machines

1 Mins read
This article was written by Follow Samuel Smith has a diverse background that includes being lead analyst and Vice President at several…
News

KB Home (KBH) Q2 2025 Earnings Call Transcript

1 Mins read
KB Home (NYSE:KBH) Q2 2025 Earnings Conference Call June 23, 2025 5:00 PM ET Company Participants Jeffrey T. Mezger – Chairman &…
News

Advance Auto Parts Stock: Rally Is Not Supported By Fundamentals (NYSE:AAP)

1 Mins read
This article was written by Follow Over fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *